Current Report Filing (8-k)
May 16 2022 - 09:16AM
Edgar (US Regulatory)
0000849636 false 0000849636 2022-05-11
2022-05-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
May 11, 2022
RESPIRERX PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Delaware |
|
1-16467 |
|
33-0303583 |
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S
Employer
Identification
No.)
|
|
126 Valley Road,
Suite C
Glen Rock,
New Jersey
|
|
07452 |
|
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code:
(201)
444-4947
(Former
name or former address, if changed since last
report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| N/A |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement.
Promissory Note Amendment
First Amendment to the Promissory Note Issued on March 31,
2021. On May 11, 2022, effective as of April 30, 2022, the
Company and Labrys Fund, LP entered into a first amendment to that
certain Promissory Note dated April 30, 2021 (“Note”) referred to
herein as “First Amendment to the Promissory Note.” The First
Amendment to the Promissory Note changes the maturity date of the
Note to July 31, 2022.
The
foregoing description of the First Amendment to the Promissory Note
does not purport to be complete and is qualified in its entirety by
reference to the First Amendment to the Promissory Note, a copy of
which is attached to this Current Report on Form 8-K as Exhibit
99.1.
Item
2.03 Creation of a Direct Financial Obligation or an Obligation
under an Off-Balance Sheet Arrangement of a
Registrant.
The
information provided in Item 1.01 of this Current Report on Form
8-K is incorporated by reference into this Item 2.03.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
*
Filed herewith
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| Date:
May 16, 2022 |
RESPIRERX PHARMACEUTICALS INC. |
| |
(Registrant) |
|
|
|
|
| |
By: |
/s/
Jeff E. Margolis |
| |
|
Jeff
E. Margolis |
| |
|
SVP,
CFO, Secretary and Treasurer |
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From May 2022 to Jun 2022
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Jun 2021 to Jun 2022
